An observational study in Rheumatoid Arthritis, Spondyloarthritis and Osteoarthritis, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 72nd largest by planned enrollment of the 134 observational ones that give a count, is one of 18 that started in 2025, is one of 135 observational ones, reaches primary completion later than 12 of the 61 other live ones, and was the 337th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
357 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 37 · Phase 3 75 · Phase 4 37
First in 2000; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 167 across the 222 interventional studies, 271 across the 134 observational. Of the 261 that completed or were terminated, 99 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 357 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 5 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
| NCT04870203Phase 3University Hospital, BordeauxCombination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | 2027-03 |
| NCT07321340Centre Hospitalier Universitaire de Saint EtienneInsole Optimization for Rheumatoid Arthritis Patients | 2026-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
Add all 16 to your calendar (.ics) → With an account.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity.
Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.
Patients with chronic rheumatological diseases (spondylitis, rheumatoid arthritis, osteoarthritis) and control population (also followed for any other pathology in the department).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the first group will correspond to those with rheumatoid arthritis according to ACR criteria of RA
Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Patients in the second group will correspond to those with spondyloarthritis according ASDAS criteria
Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Patients in the third group will correspond to those with spondyloarthritis according ACR criteria
Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Patients without rheumatic disease
Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered dietary questionnaire at baseline, 6 and 12 months.
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Describe the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism
Describes the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism using a self-assessment questionnaire (Score UPF Nova Screener) completed at baseline, 6 and 12 months.
Time frame: At baseline
Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 12 months is below that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.